Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients

Author： Watanabe Toshiaki  

Publisher： Springer Publishing Company

ISSN： 1699-048X

Source： Clinical and Translational Oncology, Vol.13, Iss.6, 2011-06, pp. : 419-425

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience

By Shimizu Toshio   Satoh Taroh   Tamura Kenji   Ozaki Tomohiro   Okamoto Isamu   Fukuoka Masahiro   Nakagawa Kazuhiko  

International Journal of Clinical Oncology, Vol. 12, Iss. 3, 2007-06 ,pp. : 218-223

Springer Publishing Company

Access to resources Recommend Favorite

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)

By Maindrault-Goebel F.   Louvet C.   Andre T.   Carola E.   Lotz J.P.   Molitor J.L.   Garcia M.L.   Gilles-Amar V.   Izrael V.   Krulik M.   de Gramont A.  

European Journal of Cancer, Vol. 35, Iss. 9, 1999-09 ,pp. : 1338-1342

Elsevier

Access to resources Recommend Favorite

Oxaliplatin with High-dose Leucovorin and 5-Fluorouracil 48-hour Continuous Infusion in Pretreated Metastatic Colorectal Cancer

By de Gramont A.   Vignoud J.   Tournigand C.   Louvet C.   Andre T.   Varette C.   Raymond E.   Moreau S.   Le Bail N.   Krulik M.  

European Journal of Cancer, Vol. 33, Iss. 2, 1997-02 ,pp. : 214-219

Elsevier

Access to resources Recommend Favorite

Nordic 5-Fluorouracil/Leucovorin Bolus Schedule Combined with Oxaliplatin (Nordic FLOX) as First-line Treatment of Metastatic Colorectal Cancer

By Sørbye Halfdan   Dahl Olav  

Acta Oncologica, Vol. 42, Iss. 8, 2003-12 ,pp. : 827-831

Informa Healthcare

Access to resources Recommend Favorite

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)

By Maindrault-Goebel F.   de Gramont A.   Louvet C.   Andre T.   Carola E.   Mabro M.   Artru P.   Gilles V.   Lotz J.P.   Izrael V.   Krulik M.   for the Oncology Multidisciplinary Research Group GERCOR  

European Journal of Cancer, Vol. 37, Iss. 8, 2001-05 ,pp. : 1000-1005

Elsevier

Access to resources Recommend Favorite